The Radoff-JEC Group Issues Letter to Fellow Seer, Inc. Stockholders Correcting the Company’s Blatant Rewriting of History

The Radoff-JEC Group, which holds about 7.7% of Seer, Inc. (NASDAQ: SEER), issued a letter to stockholders ahead of Seer’s July 28, 2026 annual meeting. It urges votes “FOR” director nominees Howard H. Berman, Joshua S. Horowitz, and Luis E. Rinaldini, citing Seer’s stock decline since its 2020 IPO and alleged governance and performance concerns.

Original reporting
Published Jul 8, 2026, 11:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 8, 2026, 11:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
The Radoff-JEC Group Issues Letter to Fellow Seer, Inc. Stockholders Correcting the Company’s Blatant Rewriting of History — source image
Decision brief

The 30-second read

$SEERBearishMed
01

Why it matters

The key market-relevant element is the proxy contest framing: alleged board non-independence, criticism of management performance, and a push for an objective strategic review process.

02

Market read

A contested director election and strategic-review push can drive short-term sentiment and positioning around SEER into the annual meeting.

03

What to watch

The article provides allegations and voting recommendations but no new, verifiable filings or outcomes; traders should watch for Seer’s formal proxy materials, board rebuttal, and any disclosed acquisition/strategic-review process details.

Relevance 4/10Novelty 4/10Timing: Ahead of Seer’s July 28, 2026 annual meeting and director vote.

Background

The Radoff-JEC Group issued a shareholder letter to Seer stockholders recommending votes for three director nominees ahead of the July 28, 2026 annual meeting.

Company-level read

Ticker impact

$SEERBearishMedium confidence
Context

Radoff-JEC, holding about 7.7% of Seer, urges votes for director nominees ahead of the July 28, 2026 annual meeting.

Expected impact

Moderate volatility risk into the July 28 annual meeting, with sentiment skewing negative if investors view the claims as credible.

Evidence & confidence

The article is a shareholder letter contesting board independence and alleging poor performance, which can influence proxy voting and perceived strategic direction, but it does not disclose new financial results or a definitive transaction.

Market effects

Limited direct sector read-across; primarily a governance and strategic-review signal for a single public biotech/health-tech name.

None material beyond US small/mid-cap sentiment around contested proxy fights.

Low; no cross-border deal, regulation, or macro catalyst described.

Counterpoint

Seer’s board may argue the letter is partisan and that the company’s strategic plan and independence structure are being mischaracterized.

Key entities

  • Seer, Inc.

    NASDAQ-listed company subject of the shareholder letter and upcoming annual meeting vote.

  • Radoff-JEC Group

    Holds about 7.7% of Seer’s outstanding common stock and recommends voting for specific director nominees.

  • Omid Farokhzad, M.D.

    CEO and Chairman whose compensation, share sales, and strategic plan are criticized in the letter.

  • Howard H. Berman, Ph.D.; Joshua S. Horowitz; Luis E. Rinaldini

    Named as director election candidates the group recommends stockholders support.

Related articles

$SEERMedAI 8/10

Two Revised, Non-Binding Proposals Seek to Acquire All of Seer's Class A Shares

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D. Rhea-AI Summary Seer (Nasdaq: SEER) confirmed receipt of two further revised, unsolicited, non-binding acquisition proposals for all outstanding shares of its Class A common stock. On July 28, 2026, the Radoff-JEC Group offered $2.55 per share in cash plus a contingent value right.

$SEERMed

Seer Stock Surges 40% After Investor Presentation Highlights AI, Growth Strategy

Seer, Inc. (SEER) shares rose about 39.8% to $2.27 on Monday after the company published an investor presentation ahead of its July 28 annual meeting. Seer cited an AI-driven proteomics strategy, commercialization progress, an expanding installed base, strategic collaborations, about $220M cash with no debt, and a stated $23B proteomics market opportunity by 2034, and urged shareholders to reject activist proposals.

$SEERMed

Seer Shares Rally 30% Following Investor Update Ahead of Annual Meeting (SEER)

Seer, Inc. (NASDAQ:SEER) shares rose about 30% after the company filed an investor presentation ahead of its July 28, 2026 annual meeting. Seer cited a $23B proteomics TAM by 2034, 62% CAGR growth in installed customers since 2021, 36% lower annual cash burn since 2022, ~$220M cash and no debt, and a $50M buyback authorization. A proxy contest is ongoing.